Tilray Brands Shows Improved Fundamentals but Needs U.S. Rescheduling to Accelerate Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Fool
- Significant International Growth: In its Q3 2026 earnings report, Tilray's international cannabis business achieved a remarkable 73% year-over-year sales growth, indicating strong potential in global markets despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which enhances its future profitability prospects.
- Improved Adjusted EBITDA: The company reported a 19% year-over-year increase in adjusted EBITDA, rising from $9 million to $10.7 million, demonstrating positive progress in cost control and operational efficiency, although it still faced a net loss of $25.2 million.
- Stable Financial Guidance: Tilray's management reiterated its financial guidance for the fiscal year ending June 30, forecasting adjusted EBITDA between $62 million and $72 million, reflecting confidence in future performance, even as the market continues to undervalue the company.
- U.S. Market Potential Unlocked: Despite ongoing discussions about the reclassification of marijuana, Tilray needs full legalization in the U.S. to leverage its cultivation capacity and enter this lucrative market, with current market valuation around $630 million indicating investor caution regarding future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 5.650
Low
8.50
Averages
9.57
High
10.00
Current: 5.650
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. Its adult-use portfolio offers a range of products, from flowers to beverages. Its beverage-alcohol portfolio includes a selection of craft beer, spirits, and beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cannabis Industry Disappointment: Tilray's Uncertain Future
- Industry Underperformance: Despite high hopes from Wall Street, Tilray Brands has seen its stock price decline over 90% in the past five years, reflecting the overall disappointing performance of the cannabis industry and diminishing investor confidence.
- Policy Change Opportunity: The U.S. government's decision to move certain cannabis products from Schedule I to Schedule III may facilitate medical cannabis research; however, it does not legalize cannabis at the federal level, leaving significant legal barriers for transportation and operations.
- Operational Efficiency Challenges: The illegality of interstate shipping forces Tilray and other cannabis companies to establish production facilities in each state, leading to significantly higher operating costs, which impacts profitability, even as policy changes may reduce some business expenses.
- Increased Competitive Pressure: Although Tilray has diversified its offerings and is now the fourth-largest craft brewer in the U.S., it faces competition from larger corporations post-potential federal legalization, and the lack of a clear competitive advantage raises uncertainties about its future prospects.
See More
U.S. Cannabis Regulatory Landscape Improves
- Industry Underperformance: Despite improvements in the U.S. cannabis regulatory environment, Tilray Brands has seen its stock price decline over 90% in the past five years, indicating a broader industry underperformance that undermines investor confidence in future growth.
- Regulatory Changes Impact: The FDA's reclassification of certain cannabis products from Schedule I to Schedule III will facilitate medical cannabis research; however, it does not legalize cannabis federally, maintaining legal barriers for interstate shipping that lead to high operational costs for companies.
- Increased Market Competition: Although Tilray offers a diverse range of CBD and cannabis products in the U.S. market, it may face intense competition from larger corporations with superior brand recognition and financial resources, potentially diminishing Tilray's market position.
- Financial Concerns: Despite becoming the fourth-largest craft brewer in the U.S. through acquisitions, Tilray continues to struggle with inconsistent revenue growth and ongoing losses, leading analysts to generally view the company's long-term outlook as unattractive, advising investors to proceed with caution.
See More
Tilray's Fundamentals Improve, But Regulatory Changes Needed for Growth
- International Business Surge: In its Q3 2026 report, Tilray's international cannabis segment achieved a remarkable 73% year-over-year sales growth, indicating strong performance in the European market, despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which may lay a foundation for future profitability.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose from $9 million to $10.7 million, reflecting a 19% year-over-year increase, showcasing progress in cost control and operational efficiency, which could bolster investor confidence moving forward.
- Dependence on U.S. Regulation: Despite improvements in fundamentals, Tilray's stock price remains highly dependent on the progress of cannabis rescheduling in the U.S.; a successful transition to Schedule III could significantly enhance its market value, while failure to do so may exert downward pressure.
- Caution for Investors: While Tilray garners attention in the market, analysts note that other cannabis stocks operating at the state level may present clearer catalysts and potentially higher returns, prompting investors to exercise caution when considering Tilray as an investment option.
See More
Tilray Brands Shows Improved Fundamentals but Needs U.S. Rescheduling to Accelerate Growth
- Significant International Growth: In its Q3 2026 earnings report, Tilray's international cannabis business achieved a remarkable 73% year-over-year sales growth, indicating strong potential in global markets despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which enhances its future profitability prospects.
- Improved Adjusted EBITDA: The company reported a 19% year-over-year increase in adjusted EBITDA, rising from $9 million to $10.7 million, demonstrating positive progress in cost control and operational efficiency, although it still faced a net loss of $25.2 million.
- Stable Financial Guidance: Tilray's management reiterated its financial guidance for the fiscal year ending June 30, forecasting adjusted EBITDA between $62 million and $72 million, reflecting confidence in future performance, even as the market continues to undervalue the company.
- U.S. Market Potential Unlocked: Despite ongoing discussions about the reclassification of marijuana, Tilray needs full legalization in the U.S. to leverage its cultivation capacity and enter this lucrative market, with current market valuation around $630 million indicating investor caution regarding future growth.
See More
Tilray Medical Joins Cannabis Europa 2026 Forum
- Industry Forum Participation: Tilray Medical's involvement in Cannabis Europa London 2026 brings together policymakers, healthcare professionals, and industry leaders to discuss the future of medical cannabis regulation and science, highlighting the company's significant role in the sector.
- Expert Panel Discussion: José Tempero, Director of International Medical Affairs, will participate in a panel titled 'Evidence First: Designing Public Policy Through Data and Trials,' emphasizing the importance of clinical research and real-world evidence in shaping responsible cannabis policy frameworks.
- Patient Support Platform: Tilray Medical co-hosts the official afterparty for Cannabis Europa London 2026 with Lyphe Clinic, which focuses on supporting patient consultations and access to medical cannabis treatments, further advancing the company's patient-centric approach in Europe.
- Global Market Positioning: Operating in over 20 highly regulated international markets, Tilray Medical supports hundreds of thousands of patients with pharmaceutical-grade cultivation, manufacturing, and distribution capabilities, showcasing its leadership in the global medical cannabis industry.
See More
Cannabis Market Potential Soars, Investment Opportunities Emerge
- Optimistic Market Outlook: According to estimates from Fortune Business Insights, the global cannabis market could exceed $1.4 trillion by 2034, up from $138 billion this year, reflecting a significant growth potential with a compound annual growth rate exceeding 34%.
- Policy Changes Impact: The recent rescheduling of FDA-approved marijuana products from Schedule I to Schedule III in the U.S. marks a significant milestone that could pave the way for future legalization, although no clear timeline exists yet, the government's consideration of marijuana benefits is a positive sign.
- Investment Risks and Opportunities: Investing in cannabis stocks like Tilray Brands carries risks due to its frequent losses and cash burn, but its stock often surges during discussions of legalization, attracting growth-oriented investors looking for significant gains.
- Advantages of Multi-State Operators: In addition to Tilray, multi-state operators such as Curaleaf Holdings and Trulieve Cannabis may benefit more directly from the rescheduling of marijuana in the U.S., making their market positions and potential returns important considerations for investors.
See More
Cannabis Industry Disappointment: Tilray's Uncertain Future
- Industry Underperformance: Despite high hopes from Wall Street, Tilray Brands has seen its stock price decline over 90% in the past five years, reflecting the overall disappointing performance of the cannabis industry and diminishing investor confidence.
- Policy Change Opportunity: The U.S. government's decision to move certain cannabis products from Schedule I to Schedule III may facilitate medical cannabis research; however, it does not legalize cannabis at the federal level, leaving significant legal barriers for transportation and operations.
- Operational Efficiency Challenges: The illegality of interstate shipping forces Tilray and other cannabis companies to establish production facilities in each state, leading to significantly higher operating costs, which impacts profitability, even as policy changes may reduce some business expenses.
- Increased Competitive Pressure: Although Tilray has diversified its offerings and is now the fourth-largest craft brewer in the U.S., it faces competition from larger corporations post-potential federal legalization, and the lack of a clear competitive advantage raises uncertainties about its future prospects.
See More
U.S. Cannabis Regulatory Landscape Improves
- Industry Underperformance: Despite improvements in the U.S. cannabis regulatory environment, Tilray Brands has seen its stock price decline over 90% in the past five years, indicating a broader industry underperformance that undermines investor confidence in future growth.
- Regulatory Changes Impact: The FDA's reclassification of certain cannabis products from Schedule I to Schedule III will facilitate medical cannabis research; however, it does not legalize cannabis federally, maintaining legal barriers for interstate shipping that lead to high operational costs for companies.
- Increased Market Competition: Although Tilray offers a diverse range of CBD and cannabis products in the U.S. market, it may face intense competition from larger corporations with superior brand recognition and financial resources, potentially diminishing Tilray's market position.
- Financial Concerns: Despite becoming the fourth-largest craft brewer in the U.S. through acquisitions, Tilray continues to struggle with inconsistent revenue growth and ongoing losses, leading analysts to generally view the company's long-term outlook as unattractive, advising investors to proceed with caution.
See More
Tilray's Fundamentals Improve, But Regulatory Changes Needed for Growth
- International Business Surge: In its Q3 2026 report, Tilray's international cannabis segment achieved a remarkable 73% year-over-year sales growth, indicating strong performance in the European market, despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which may lay a foundation for future profitability.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose from $9 million to $10.7 million, reflecting a 19% year-over-year increase, showcasing progress in cost control and operational efficiency, which could bolster investor confidence moving forward.
- Dependence on U.S. Regulation: Despite improvements in fundamentals, Tilray's stock price remains highly dependent on the progress of cannabis rescheduling in the U.S.; a successful transition to Schedule III could significantly enhance its market value, while failure to do so may exert downward pressure.
- Caution for Investors: While Tilray garners attention in the market, analysts note that other cannabis stocks operating at the state level may present clearer catalysts and potentially higher returns, prompting investors to exercise caution when considering Tilray as an investment option.
See More
Tilray Brands Shows Improved Fundamentals but Needs U.S. Rescheduling to Accelerate Growth
- Significant International Growth: In its Q3 2026 earnings report, Tilray's international cannabis business achieved a remarkable 73% year-over-year sales growth, indicating strong potential in global markets despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which enhances its future profitability prospects.
- Improved Adjusted EBITDA: The company reported a 19% year-over-year increase in adjusted EBITDA, rising from $9 million to $10.7 million, demonstrating positive progress in cost control and operational efficiency, although it still faced a net loss of $25.2 million.
- Stable Financial Guidance: Tilray's management reiterated its financial guidance for the fiscal year ending June 30, forecasting adjusted EBITDA between $62 million and $72 million, reflecting confidence in future performance, even as the market continues to undervalue the company.
- U.S. Market Potential Unlocked: Despite ongoing discussions about the reclassification of marijuana, Tilray needs full legalization in the U.S. to leverage its cultivation capacity and enter this lucrative market, with current market valuation around $630 million indicating investor caution regarding future growth.
See More
Tilray Medical Joins Cannabis Europa 2026 Forum
- Industry Forum Participation: Tilray Medical's involvement in Cannabis Europa London 2026 brings together policymakers, healthcare professionals, and industry leaders to discuss the future of medical cannabis regulation and science, highlighting the company's significant role in the sector.
- Expert Panel Discussion: José Tempero, Director of International Medical Affairs, will participate in a panel titled 'Evidence First: Designing Public Policy Through Data and Trials,' emphasizing the importance of clinical research and real-world evidence in shaping responsible cannabis policy frameworks.
- Patient Support Platform: Tilray Medical co-hosts the official afterparty for Cannabis Europa London 2026 with Lyphe Clinic, which focuses on supporting patient consultations and access to medical cannabis treatments, further advancing the company's patient-centric approach in Europe.
- Global Market Positioning: Operating in over 20 highly regulated international markets, Tilray Medical supports hundreds of thousands of patients with pharmaceutical-grade cultivation, manufacturing, and distribution capabilities, showcasing its leadership in the global medical cannabis industry.
See More
Cannabis Market Potential Soars, Investment Opportunities Emerge
- Optimistic Market Outlook: According to estimates from Fortune Business Insights, the global cannabis market could exceed $1.4 trillion by 2034, up from $138 billion this year, reflecting a significant growth potential with a compound annual growth rate exceeding 34%.
- Policy Changes Impact: The recent rescheduling of FDA-approved marijuana products from Schedule I to Schedule III in the U.S. marks a significant milestone that could pave the way for future legalization, although no clear timeline exists yet, the government's consideration of marijuana benefits is a positive sign.
- Investment Risks and Opportunities: Investing in cannabis stocks like Tilray Brands carries risks due to its frequent losses and cash burn, but its stock often surges during discussions of legalization, attracting growth-oriented investors looking for significant gains.
- Advantages of Multi-State Operators: In addition to Tilray, multi-state operators such as Curaleaf Holdings and Trulieve Cannabis may benefit more directly from the rescheduling of marijuana in the U.S., making their market positions and potential returns important considerations for investors.
See More
